HEIDELBERG, Germany, May 30, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its Chief Executive Officer, Dr. Adi Hoess, will present at the 2023 Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 8:30 a.m. Eastern Daylight Time / 14:30 Central European Time.

A live webcast of the presentation will be accessible on Affimed’s website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/. A replay of the call will be archived on Affimed’s website for 30 days after the call.

For more information on the conference or to schedule a one-on-one meeting with Affimed’s management, please contact Jefferies or Alex Fudukidis via email at This email address is being protected from spambots. You need JavaScript enabled to view it. or phone at +1 (917) 436-8102.

About Affimed N.V.

Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company’s proprietary ROCK^® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK^® platform predictably generates customized innate cell engager (ICE^®) molecules, which use patients’ immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE^®. Headquartered in Heidelberg, Germany, with offices in New York, NY, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients’ lives. For more about the Company’s people, pipeline and partners, please visit: www.affimed.com.

Investor Relations Contact
Alexander Fudukidis
Director, Head of Investor Relations
E-Mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel.: +1 (917) 436-8102